"Pancreatic cancer" from_date:2012

Pancreatic cancer Skip to main contentSkip to searchAbout usHelpSubscribeAccess through your institutionLog inBMJ Best PracticeSearchSearchSelect languagePancreatic cancer MENULog in or subscribe to access all of BMJ Best PracticeLast reviewed:30 Jul 2023Last updated:24 Aug 2023SummaryPancreatic cancer is the sixth most common cause of cancer-related death in Europe.Most common presentation pancreatic neoplasms.[1]​​ The course of pancreatic cancer has been shown to follow a linear progression model from pre-invasive pancreatic intraepithelial neoplastic lesions to invasive ductal adenocarcinoma. Two additional well-defined precursor lesions are the intraductal papillary mucinous neoplasm and the mucinous cystic neoplasm.[2]For diagnosis and management of neuroendocrine tumours

Olaparib for maintenance treatment of BRCA mutation-positive metastatic pancreatic cancer after platinum-based chemotherapy (terminated appraisal) Olaparib for maintenance treatment of BRCA mutation-positive metastatic pancreatic cancer after platinum-based chemotherapy (terminated appraisal) Technology appraisal guidance Published: 8 December 2021 www.nice.org.uk/guidance/ta750 © NICE 2021. All ...........................................................................................................................................................................3 Olaparib for maintenance treatment of BRCA mutation-positive metastatic pancreatic cancer afterplatinum-based chemotherapy (terminated appraisal) (TA750)© NICE 2021. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of-rights).Page 2 of3Advice Advice NICE is unable to make a recommendation about the use in the NHS of olaparib for maintenance

Report on the National Pancreatic Cancer Roadmap

Permanent implant brachytherapy devices for unresectable pancreatic cancer AAAReports & Guidance > Permanent implant brachytherapy devices for unresectable pancreatic cancerPermanent implant brachytherapy devices for unresectable pancreatic cancerTOPIC STATUS Incomplete Pancreatic cancer is the 10th most common cancer in the UK and is often diagnosed at a stage when surgery

Irinotecan liposome injection with oxaliplatin, 5-fluorouracil and leucovorin for previously untreated metastatic pancreatic cancer Irinotecan liposome injection with oxaliplatin, 5-fluorouracil and leucovorin for previously untreated metastatic pancreatic cancer - NIHR Innovation Observatory * Who we are * What we do * Our Networks * Engage * Events * News * Resources Get in touch * * A world injection with oxaliplatin, 5-fluorouracil and leucovorin for previously untreated metastatic pancreatic cancerIrinotecan liposome injection with oxaliplatin, 5-fluorouracil and leucovorin is in development for the treatment of metastatic pancreatic cancer. Pancreatic cancer occurs when abnormal cells in the pancreas divide and grow in an uncontrolled way, forming a growth (tumour). Irinotecan liposome

Clinical Practice Guidelines for Pancreatic Cancer 2022 from the Japan Pancreas Society: a synopsis Clinical Practice Guidelines for Pancreatic Cancer was first published in 2006 by the Japan Pancreas Society, and revised in 2009, 2013, 2016, and 2019. In July 2022, Clinical Practice Guidelines for Pancreatic Cancer was newly revised in Japanese. For this revision, we developed an entirely new , chemotherapy, and precision medicine of pancreatic cancer, and addresses 7 subjects: diagnosis, surgical therapy, adjuvant therapy, radiation therapy, chemotherapy, stent therapy, and supportive & palliative medical care. It includes 73 clinical questions and 112 statements. The statements correspond to the clinical questions, evidence levels, recommendation strengths, and agreement rates. This guideline

Pancreatic Cancer Skip to main contentAn official website of the United States governmentEspañolMenuSearchHome Cancer Types Pancreatic Cancer Health Professional Pancreatic Cancer Treatment (PDQ®)–Health Professional VersionPrintEmailPancreatic Cancer Treatment (PDQ®)–Health Professional VersionGo to Patient VersionON THIS PAGEGeneral Information About Pancreatic CancerCellular Classification This SectionIncidence and MortalityRisk FactorsAnatomyClinical FeaturesDiagnostic and Staging EvaluationImagingPeritoneal cytologyTumor markersPrognosis and SurvivalPalliative TherapyThis summary provides information about the treatment of exocrine pancreatic cancer.Incidence and MortalityEstimated new cases and deaths from pancreatic cancer in the United States in 2023:[1]New cases: 64,050.Deaths: 50,550

Pancreatic Cancer, Childhood Skip to main contentAn official website of the United States governmentEspañolMenuSearchHome Cancer Types Pancreatic Cancer Health Professional Childhood Pancreatic Cancer Treatment (PDQ®)–Health Professional VersionPrintEmailChildhood Pancreatic Cancer Treatment (PDQ®)–Health Professional VersionGo to Patient VersionON THIS PAGEGeneral Information About Childhood population, and the lack of clinical trials for adolescents with rare cancers.Information about these tumors may also be found in sources relevant to adults with cancer, such as Pancreatic Cancer Treatment and Pancreatic Neuroendocrine Tumors (Islet Cell Tumors) Treatment.ReferencesSmith MA, Seibel NL, Altekruse SF, et al.: Outcomes for children and adolescents with cancer: challenges for the twenty-first

Guidelines for permanent iodine-125 seed interstitial brachytherapy for pancreatic cancer (2023 edition): The Chinese expert consensus workshop report The incidence of pancreatic cancer is increasing worldwide. Approximately, 60% of patients with pancreatic cancer have distant metastases at the time of diagnosis, of which only 10% can be removed using standard resection. Further, patients derive

American Society for Gastrointestinal Endoscopy guideline on screening for pancreatic cancer in individuals with genetic susceptibility: methodology and review of evidence GUIDELINEAmerican Society for Gastrointestinal Endoscopy guideline onscreening for pancreatic cancer in individuals with geneticsusceptibility: methodology and review of evidenceAudrey H. Calderwood, MD, MS, FASGE,1,*Mandeep S . Our guidelines shouldnot be used in support of medical complaints, legal pro-ceedings, and/or litigation because they were not de-signed for this purpose.The American Society for Gastrointestinal Endoscopy(ASGE) Standards of Practice Committee has developedguidelines for pancreatic cancer screening in individuals atincreased risk of pancreatic cancer because of genetic sus-ceptibility

ASGE guideline on screening for pancreatic cancer in individuals with genetic susceptibility: summary and recommendations GUIDELINEASGE guideline on screening for pancreatic cancer inindividuals with genetic susceptibility: summary andrecommendationsMandeep S. Sawhney, MD, MS, FASGE,1,*Audrey H. Calderwood, MD, MS, FASGE,2,*Nirav C. Thosani, MD, MHA,3Timothy R. Rebbeck, PhD,4Sachin Wani, MD over the next decade.4Biologically aggressivebehavior, advanced stage at the time of diagnosis, and poorresponse to oncologic therapies have been proposed asreasons for dismal outcomes in pancreatic cancer.5Diagnosis at earlier stages of disease is associated withimproved survival, with 93% 10-year survival among stage0 cancers and 34% to 39% 5-year survival among stage I can-cers.6,7However

Development of Multiparametric Prognostic Models for Stereotactic MR-guided Radiotherapy of Pancreatic Cancers: Prognostic Models for Pancreatic Cancers SMART. SMART is a new option of local treatment for unresectable PDAC, showing interesting survival and local control results. Despite this, some patients will experience early local and/or metastatic recurrence leading to death. We aimed

Korean Surgical Practice Guideline for Pancreatic Cancer 2022: A summary of evidence-based surgical approaches PROSPEROInternational prospective register of systematic reviews Print | PDFDoes Sex Affect the Efficacy of Systemic Pharmacological Treatments of Pain in Knee Osteoarthritis? A Systematic ReviewSantiago Espinosa-Salas, Thomas Schnitzer, Eileen WaffordTo enable PROSPERO to focus

National guidelines for diagnosis and treatment of pancreatic cancer 2022 in China

Duodenal obstruction 1.7.6 During attempted resection for head of pancreas cancer, consider prophylactic gastrojejunostomy if the cancer is found to be unresectable. 1.7.7 If possible, relieve symptomatic duodenal obstruction caused by unresectable pancreatic cancer. 1.7.8 When deciding between gastrojejunostomy and duodenal stent placement, consider gastrojejunostomy for people with a more favourable of a clinical trial. Surgery Surgery 1.8.3 For people having surgery for head of pancreas cancer, consider pylorus-preserving resection if the tumour can be adequately resected. 1.8.4 Consider standard lymphadenectomy, rather than extended lymphadenectomy Pancreatic cancer in adults: diagnosis and management (NG85)© NICE 2022. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms

Automated CAD system for early detection and classification of pancreatic cancer using deep learning model. Accurate diagnosis of pancreatic cancer using CT scan images is critical for early detection and treatment, potentially saving numerous lives globally. Manual identification of pancreatic tumors by radiologists is challenging and time-consuming due to the complex nature of CT scan images , and an overall system average processing time of 1.51 seconds, demonstrating the capability of the system to effectively and efficiently identify and classify pancreatic cancers.

Effect of cytotoxic CD8+ T-cells secretory proteins on hypoxic pancreatic cancer cells. Hypoxia in tumor cells is linked to increased drug resistance and more aggressive behavior. In pancreatic cancer, the tumor microenvironment is notably hypoxic and exhibits strong immunosuppressive properties. Given that immunotherapy is now approved for pancreatic cancer treatment, further understanding

The choice of adjuvant radiotherapy in pancreatic cancer patients after up-front radical surgery. The role of adjuvant radiotherapy in pancreatic cancer following radical surgery remains a subject of of controversy. This study aimed to more accurately screen pancreatic patients who benefit from adjuvant radiotherapy. Clinicopathologic characteristics of patients with resectable pancreatic cancer mortality rate and cancer-specific mortality rate compared to those without radiotherapy (all p < 0.05). Subgroup analysis indicated N1 stage pancreatic cancer patients with T2-4 stage, primary focus on the head of the pancreas, young age of onset, and combination chemotherapy were in favor of the adjuvant radiotherapy group (all p < 0.05). Our analysis demonstrates that adjuvant radiotherapy may

Maintenance olaparib (Lynparza) for the treatment of patients with germline BRCA-mutated metastatic pancreatic cancer Maintenance olaparib (Lynparza®) for the treatment of patients with germline BRCA-mutated metastatic pancreatic cancer. Update July 2020 - Repository of AIHTA GmbH English | Deutsch Atom RSS 1.0 RSS 2.0 * Simple search * Advanced search * Help * Services * Login * Browse * Type * Subject * Author / Editor * Institution * YearAIHTA - Publications - Search - Maintenance olaparib (Lynparza®) for the treatment of patients with germline BRCA-mutated metastatic pancreatic cancer. Update July 2020 Grössmann, N.(2020):Maintenance olaparib (Lynparza®) for the treatment of patients with germline BRCA-mutated metastatic pancreatic cancer. Update July 2020. Oncology Fact Sheet Nr. 11

Irreversible electroporation for treating pancreatic cancer Irreversible electroporation for treating pancreatic cancer Interventional procedures guidance Published: 3 May 2017 www.nice.org.uk/guidance/ipg579 Your responsibility Your responsibility This guidance represents the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement cancer is inadequate in quantity and quality. Therefore, this procedure should only be used in the context of research. 1.2 Further research, preferably in the form of randomised controlled trials, should assess the effect of the procedure on local tumour control, patient survival, pain control and quality of life. 2 2 Indications and current treatments Indications and current treatments 2.1 Pancreatic